Literature DB >> 10536987

Sulfur containing tyrosine analogs can cause selective melanocytotoxicity involving tyrosinase-mediated apoptosis.

Y Minamitsuji1, K Toyofuku, S Sugiyama, K Yamada, K Jimbow.   

Abstract

Sulfur-containing tyrosine analogs such as 4-S-cysteaminylphenol (4-S-CAP) and its N-acetyl derivative, N-acetyl-4-S-CAP, are tyrosinase substrates and can cause selective cytotoxicity or cell death of melanocytes and melanoma cells. It is not clear, however, if the cytotoxicity derives from a cytostatic or cytocidal effect. The latter can also be either apoptotic or necrotic. This paper summarizes our attempt to clarify the nature of melanocytotoxicity and cell death by using a new derivative of 4-S-CAP, N-propionyl-4-S-CAP (NPr-CAP). The i.p. administration of NPr-CAP caused marked depigmentation of black hair follicles in C57 mice. At 12 h postadministration of NPr-CAP, follicular melanocytes showed histochemical and morphologic features indicative of apoptosis by TdT-mediated dUTP-biotin nick end labeling (TUNEL) staining and electron microscopy. The agarose gel electrophoresis of DNA from drug-treated melan a2 cells, an immortal melanocyte line of C57 black mice, showed the nucleosomal DNA ladder pattern. NPr-CAP caused irreversible cytotoxicity in melan a2 and the effect was inhibited by a tyrosinase inhibitor, phenylthiocarbamide. The tyrosinase-mediated cytotoxicity of NPr-CAP was further confirmed by the decreased viability of COS 7 monkey-kidney cells, which expressed a level of high tyrosinase activity through transfection of human tyrosinase cDNA. NPr-CAP, however, also transiently inhibited the proliferation of melan c cells, a control tyrosinase-negative albino melanocyte line, and vector-transfected COS 7 cells. Thus, the major process of NPr-CAP-mediated melanocytotoxicity involves cytocidal apoptosis associated with active tyrosinase. In addition, there is transient, nontyrosinase-mediated cytostatic cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536987     DOI: 10.1038/sj.jidsp.5640196

Source DB:  PubMed          Journal:  J Investig Dermatol Symp Proc        ISSN: 1087-0024


  4 in total

1.  Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles.

Authors:  Kowichi Jimbow; Yasue Ishii-Osai; Shosuke Ito; Yasuaki Tamura; Akira Ito; Akihiro Yoneta; Takafumi Kamiya; Toshiharu Yamashita; Hiroyuki Honda; Kazumasa Wakamatsu; Katsutoshi Murase; Satoshi Nohara; Eiichi Nakayama; Takeo Hasegawa; Itsuo Yamamoto; Takeshi Kobayashi
Journal:  J Skin Cancer       Date:  2013-02-21

Review 2.  Emergent Nanotechnological Strategies for Systemic Chemotherapy against Melanoma.

Authors:  Jacinta Oliveira Pinho; Mariana Matias; Maria Manuela Gaspar
Journal:  Nanomaterials (Basel)       Date:  2019-10-13       Impact factor: 5.076

3.  Growth inhibition of re-challenge B16 melanoma transplant by conjugates of melanogenesis substrate and magnetite nanoparticles as the basis for developing melanoma-targeted chemo-thermo-immunotherapy.

Authors:  Tomoaki Takada; Toshiharu Yamashita; Makito Sato; Akiko Sato; Ichiro Ono; Yasuaki Tamura; Noriyuki Sato; Atsushi Miyamoto; Akira Ito; Hiroyuki Honda; Kazumasa Wakamatsu; Shosuke Ito; Kowichi Jimbow
Journal:  J Biomed Biotechnol       Date:  2009-10-08

Review 4.  Elucidation of Melanogenesis Cascade for Identifying Pathophysiology and Therapeutic Approach of Pigmentary Disorders and Melanoma.

Authors:  Tokimasa Hida; Takafumi Kamiya; Akinori Kawakami; Jiro Ogino; Hitoshi Sohma; Hisashi Uhara; Kowichi Jimbow
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.